newsfilter
← Latest News
GlobeNewswire·

Oxbryta® (voxelotor) Tablets for Oral Suspension, A New Dispersible Tablet Dosage Form, Now Available for Patients with Sickle Cell Disease in the United States

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced Oxbryta® (voxelotor) tablets for oral suspension, a new dispersible, once-daily tablet dosage form recently approved by